Jeroen van de Pol

109 4 Cost-utility and cost-effectiveness analysis of a clinical medication review Table 2: Mean costs per time point for each cost category between control and intervention group. At each time point the costs are calculated over the three months before. NB. Data are presented as mean costs ± standard deviation. Cost category Control group (n = 294) Intervention group (n = 294) Baseline T1: 3 months T2: 6 months Baseline T1: 3 months T2: 6 months Drugs 454 ± 873 434 ± 519 439 ± 365 383 ± 277 400 ± 316 433 ± 671 Primary care 206 ± 293 193 ± 293 221 ± 308 174 ± 245 186 ± 259 160 ± 232 Secondary care 330 ± 1,087 325 ± 926 430 ± 1,261 272 ± 723 323 ± 1,181 377 ± 1,197 Institutional care 24 ± 205 273 ± 2,227 205 ± 1,757 43 ± 472 114 ± 174 197 ± 2,074 Home care 473 ± 1,031 574 ± 1,551 627 ± 1,433 544 ± 1,203 605 ± 1,579 688 ± 1,697 Informal care 152 ± 1,046 315 ± 1,421 159 ± 1,025 119 ± 6,034 164 ± 849 159 ± 1,258